AstraZeneca (AZ) has announced that new real-world data from Canada shows its COVID-19 vaccine – Vaxzevria – was found to be highly effective after one dose against severe disease or hospitalisation caused by the Beta and Delta variants.
The pre-print results, from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health, showed one dose of Vaxzevria was 82% effective against hospitalisation or death caused by the Beta and Gamma COVID-19 variants.
On top of that, AZ’s jab showed high efficacy against the Delta and Alpha variants, showing an 87% reduction and 90% reduction of hospitalisations or deaths respectively.
One dose of Vaxzevria had lower efficacy against milder symptomatic disease than against severe disease, although AZ added that the indicated two dose schedule of the vaccine is known to enhance efficacy in this disease setting.
The vaccine’s effectiveness against any symptomatic disease was 50% for the Beta or Gamma variants, and 70% and 72% against the Delta and Alpha variants respectively.
The analysis included 69,533 individuals who tested positive for COVID-19 from December 2020 to May 2021 in Ontario, Canada, with 28,705 testing positive for non-variants of concern and 40,828 testing positive for a variant of concern.
“With different variants threatening to disrupt our route out of the pandemic, this real-world evidence shows that Vaxzevria, along with other vaccines used in Canada, provides a high level of protection against the most serious forms of the disease, even after just one shot,” Said Mene Pangalos, executive vice president, BioPharmaceuticals R&D at AZ.
“It is essential that we continue to protect as many people as possible in all corners of the world in order to get ahead of this deadly virus,” he added.
The amendment makes QR codes mandatory on every active pharmaceutical ingredient. The Amendment Rules will come into force from January 01, 2023.
On June 22, 2022, the Commission adopted pioneering proposals to restore damaged ecosystems and bring nature back across Europe, from agricultural land and seas, to forests and urban environments. The Commission also proposes to reduce the use and risk of chemical pesticides by 50% by 2030.
According to New York Times, in a small clinical trial, 18 patients took a drug called Dostarlimab for around six months, and in the end, every one of them saw their tumours disappear.
As the war in Ukraine and pandemic disruptions continue to wreak havoc on supply chains, stagflation is here to stay – marked by low growth and high inflation for at least the next 12 months.
The pandemic as well as the war in Ukraine have stifled supply of commodities and goods and upended efficient distribution through global supply chains, forcing up prices of everyday goods such as fuel and food.
Roche and its subsidiary TIB Molbiol have developed three unique LightMix® Modular Virus kits in response to recent monkeypox virus concerns. Multiple clusters of the monkeypox virus have been reported within the past two weeks in several European countries and North America, which are regions where the virus is not normally found.
The strictest COVID -19 lockdown in China since the pandemic began has resulted in container goods sitting at Shanghai’s port for nearly two weeks.
New anti-counterfeit technology, called a cyber-physical watermark, leverages edible fluorescent silk to identify medications.
The global economy — already struggling with war in Ukraine and the stagflation risks it’s fanning — is bracing for greater disruption as China scrambles to contain its worst outbreak of Covid-19 since the pandemic began.
Oil prices surged past $100 (£74) a barrel to hit their highest level for more than seven years after Russia launched an invasion of Ukraine.